Journal: Arthritis Research & Therapy
Article Title: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus
Figure Lengend Snippet: Dose-dependent depletion by daratumumab of plasma cells and plasmablasts from peripheral blood mononuclear cell (PBMC) samples ex vivo. a Representative fluorescence-activated cell sorting (FACS) plot of combined plasma cells/plasmablasts. Shown is pre-gated on live singlet CD3 − CD56 − CD19 low/mid CD20 − lymphocytes. From left to right, plot shows the representative plasma cell/plasmablast population at 1 μg/ml isotype control, 0.0003 μg/ml daratumumab, 0.01 μg/ml daratumumab and 1 μg/ml daratumumab (Dara), respectively. Number in the quadrant shows absolute number of CD27 hi CD38 hi plasma cells-plasmablasts in each condition at 72 h post-culture. b Quantification of plasma cell/plasmablast number at 72 h post-culture with isotype control or daratumumab at indicated concentrations. c Dose-response of plasma cell/plasmablast depletion by daratumumab in all donors with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) and healthy donors combined. d Representative FACS plot of CD27 − IgD − memory B cell, CD27 + IgD − class-switched memory B cell and CD27 + IgD + non-class-switched memory B cell at 72 h post-culture in the presence of daratumumab at each indicated concentration. Number in the quadrant shows absolute number of each memory B cell subset. e - g Slight increase in non-class-switched memory B cell ( e ), CD27 + class-switched memory B cell ( f ) and CD27 − memory B cell ( g ) compared to isotype control at each indicated concentration. For each individual donor at each daratumumab concentration, triplicate wells were combined for quantification in a , b and d and then normalized to isotype control in c and e - g Data shown represent four healthy controls, five donors with SLE and four with RA
Article Snippet: PBMC samples for CD38 expression analysis from patients with SLE and RA and from healthy donors were acquired from Bioreclamation (Westbury, NY, USA) and Precision for Medicine (Frederick, MD, USA).
Techniques: Ex Vivo, Fluorescence, FACS, Concentration Assay